The EU-funded project “Ubiquitous Pharmacogenomics“ (U-PGx) is part of the Horizon 2020 program and aimes at driving the implementation of pharmacogenetics in diagnostic and clinical practice. The objective is to treat patients with medication and doses that are ideally suited to their personal genetic make-up. This is based on the fact that there is a known relationship between the individual effect of these drugs and the patient’s individal DNA variants (pharmacogenetics).
As part of this project, bio.logis digital health GmbH (formerly Genetic Information Management GmbH) provides its platform GIMS. GIMS supports genetic laboratories in translating analysis results into leverageable clinical information and recommended action. The IT solution enables the efficient automated production of diagnostic reports as well as the digital delivery of results and information to physicians and patients. Over the course of the next five years, seven notable European university hospitals will analyze the genetic make-up of over 8,000 patients taking one of 84 selected drugs.
To get more information please read the attached U-PGx brochure or our press release about the successful launch of bio.logis GIMS in this project.
"Ubiquitous Pharmacogenetics“ (UPGx):
Das Europäische Projekt zur klinischen Implementierung von pharmakogenetischem Expertenwissen mittels digitaler Lösungen."